Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

HealthStream Announces Third Quarter 2021 Results


HealthStream, Inc. (Nasdaq: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, announced today results for the third quarter ended September 30, 2021.

Financial Results:
Third Quarter 2021 Compared to Third Quarter 2020
Revenues for the third quarter of 2021 increased by $3.2 million, or five percent, to $64.1 million, compared to $60.9 million for the third quarter of 2020.

Revenues from our Workforce Solutions segment were $51.2 million for the third quarter of 2021, an increase of four percent compared to $49.2 million for the third quarter of 2020. The workforce segment achieved this four percent growth while overcoming a $9.2 million decline in revenues from the legacy resuscitation business. Revenues from recent acquisitions and growth in other solutions more than offset this decline in legacy resuscitation revenues. In addition, workforce revenues also benefitted from a $0.5 million increase in professional services revenues, primarily associated with recently acquired businesses.

Revenues from our Provider Solutions segment were $12.9 million for the third quarter of 2021, compared to $11.7 million for the third quarter of 2020. This revenue growth of $1.2 million was primarily attributable to subscription revenues.

Generally accepted accounting principles (GAAP) require companies to write down beginning balances of acquired deferred revenue as part of "fair value" accounting. During the third quarter of 2021, HealthStream reported a reduction of $800,000 to revenue and operating income and a reduction of $630,000 to net income as a result of deferred revenue write-downs from recent acquisitions. During the third quarter of 2020, HealthStream reported a reduction of $80,000 to revenue and operating income and a reduction of $60,000 to net income as a result of deferred revenue write-downs from prior acquisitions.

1 Adjusted EBITDA is a nonGAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release.

Operating income was $1.8 million for the third quarter of 2021, compared to $3.1 million from the third quarter of 2020. The decrease in operating income was primarily attributable to higher operating expenses and amortization, primarily associated with businesses acquired over the past twelve months.

Net income was $1.5 million in the third quarter of 2021, down 43 percent from $2.6 million in the third quarter of 2020, and EPS was $0.05 per share (diluted) in the third quarter of 2021, compared to $0.08 per share (diluted) for the third quarter of 2020.

Adjusted EBITDA was $12.5 million for the third quarter of 2021, up 12 percent from $11.2 million in the third quarter of 2020.

At September 30, 2021, the Company had cash and cash equivalents and marketable securities of $60.6 million. Capital expenditures incurred during the third quarter of 2021 were $5.6 million.

Year-to-Date 2021 Compared to Year-to-Date 2020

For the first nine months of 2021, revenues were $192.4 million, an increase of five percent over revenues of $183.0 million for the first nine months of 2020. Operating income for the first nine months of 2021 decreased by 42 percent to $8.5 million, compared to $14.7 million for the first nine months of 2020. The decrease in operating income was primarily attributable to the $3.4 million one-time favorable contractual adjustment to royalty expense resulting in a reduction to cost of revenues in the first quarter of 2020. Also contributing to the decrease are higher operating expenses primarily associated with acquisitions completed over the past twelve months. Partially offsetting these declines in operating income was a $1.0 million non-recurring, non-cash benefit during the first quarter of 2021 related to the reduction of paid time off (PTO) expense resulting from modifications to the Company's PTO policy. Net income for the first nine months of 2021 decreased to $6.2 million, compared to $13.2 million for the first nine months of 2020. Earnings per share were $0.20 per share (diluted) for the first nine months of 2021, compared to $0.41 per share (diluted) for the first nine months of 2020. Adjusted EBITDA increased by 15 percent to $40.6 million for the first nine months of 2021, compared to $35.2 million for the first nine months of 2020.

Other Business Updates

At September 30, 2021, we had approximately 4.92 million contracted subscriptions to hStreamtm, our Platform-as-a-Service technology. hStream technology enables healthcare organizations and their respective workforces to easily connect to and gain value from the growing HealthStream ecosystem of applications, tools, and content.

Financial Outlook for 2021

The Company is updating its guidance for 2021 for the measures set forth below. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to projected net income (the most comparable GAAP measure) for 2021, see the table included on page nine of this release.

 

 

Full Year 2021 Guidance

Revenue

 

 

 

 

 

 

 

 

 

 

Workforce Solutions

 

$

205.0

 

-

 

$

206.5

 

million

Provider Solutions

 

 

50.5

 

-

 

 

51.0

 

million

Consolidated

 

$

255.5

 

-

 

$

257.5

 

million

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA1

 

$

51.0

 

-

 

$

53.0

 

million

 

 

 

 

 

 

 

 

 

 

 

Capital Expenditures

 

$

25.0

 

-

 

$

26.0

 

million

 

1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release.

The Company's guidance for 2021 as set forth above reflects the Company's assumptions regarding, among other things, the COVID-19 pandemic as noted below, anticipated integration costs and additional investments in sales, marketing, and product development in 2021 for recently acquired companies, and estimated deferred revenue write-downs of $4.0 million during 2021 related to recent acquisitions, which would result in corresponding reductions to net revenues and operating income during 2021.

The Company's financial guidance assumes that public health conditions associated with the pandemic and general economic conditions (including conditions impacting healthcare organizations) continue to improve over the course of the year, including that COVID-19 vaccines continue to be successfully distributed and perform according to current expectations and that new variants of the virus, or other unknown variants, do not further impede recovery from the pandemic.

Commenting on third quarter 2021 results, Robert A. Frist, Jr., Chief Executive Officer of HealthStream, said, "Our results this quarter position us well to finish the year strong?as reflected in our updated financial guidance, which includes an expected record adjusted EBITDA of between $51 million to $53 million. Our third quarter revenues were up five percent over the prior year quarter, which is indicative of the growth that was necessary to offset and rise above the previously announced headwind of declining legacy resuscitation revenues. This meaningful growth was achieved through the progress made in sales and implementations of product suites like the American Red Cross, CredentialStream, and Jane, along with our newly acquired scheduling businesses. We are excited to finish 2021 and start 2022 with this innovative, growing portfolio of applications and solutions."

A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Vice President of Investor Relations and Corporate Communications, will be held on Tuesday, October 26, 2021, at 9:00 a.m. (ET). To listen to the conference, please dial 877-647-2842 (no conference ID needed) if you are calling within the domestic U.S. or Canada. If you are an international caller, please dial 914-495-8564 (no conference ID needed). The conference may also be accessed by going to http://ir.healthstream.com/events.cfm for the simultaneous Webcast of the call, which will subsequently be available for replay. The replay telephone numbers are 855-859-2056 (conference ID #1766802) for U.S. and Canadian callers and 404-537-3406 (conference ID #1766802) for international callers.

Use of Non-GAAP Financial Measures

This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company's financial results and ongoing operational performance. In order to better assess the Company's financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses and before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, the de-recognition of non-cash expense resulting from the PTO expense reduction in the first quarter of 2021, and the resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 ("adjusted EBITDA") is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company's ongoing operating performance and to compare the Company's operating performance between periods. In addition, beginning in 2021, executive bonuses are based on the achievement of adjusted EBITDA targets.

As noted above, the definition of adjusted EBITDA includes an adjustment for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. Following the completion of any acquisition by the Company, the Company must record the acquired deferred revenue at fair value as defined in GAAP, which may result in a write-down of deferred revenue. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods. Revenue for any such acquired business is deferred and is typically recognized over a one-to-two-year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two-year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. Management believes that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for acquired businesses provides useful information to investors because the deferred revenue write-down recognized in periods after an acquisition may, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance and thus adjusting for this amount may assist in comparing the Company's results of operations between periods.

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool.

This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of adjusted EBITDA to net income (the most comparable GAAP measure), which is set forth below in this release.

About HealthStream

HealthStream (Nasdaq: HSTM) is dedicated to improving patient outcomes through the development of healthcare organizations' greatest asset: their people. Our unified suite of solutions is contracted by healthcare organizations across the U.S. for workforce development, training & learning management, nurse & staff scheduling, clinical education, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. HealthStream's corporate office is in Nashville, Tennessee. For more information, visit http://www.healthstream.com or call 800-521-0574.

HEALTHSTREAM, INC.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September

30, 2021

 

 

September

30, 2020

 

 

September

30, 2021

 

 

September

30, 2020

 

Revenues, net

 

$

64,091

 

 

$

60,883

 

 

$

192,374

 

 

$

183,008

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues (excluding depeciation and amortization)

 

 

22,585

 

 

 

23,302

 

 

 

68,053

 

 

 

66,596

 

Product development

 

 

10,344

 

 

 

8,192

 

 

 

30,205

 

 

 

23,491

 

Sales and marketing

 

 

10,232

 

 

 

8,863

 

 

 

28,713

 

 

 

26,286

 

Other general and administrative expenses

 

 

10,004

 

 

 

9,986

 

 

 

29,445

 

 

 

29,949

 

Depreciation and amortization

 

 

9,141

 

 

 

7,406

 

 

 

27,443

 

 

 

22,005

 

Total operating costs and expenses

 

 

62,306

 

 

 

57,749

 

 

 

183,859

 

 

 

168,327

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income

 

 

1,785

 

 

 

3,134

 

 

 

8,515

 

 

 

14,681

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (loss) income, net

 

 

(99

)

 

 

100

 

 

 

(250

)

 

 

2,006

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income tax provision

 

 

1,686

 

 

 

3,234

 

 

 

8,265

 

 

 

16,687

 

Income tax provision

 

 

186

 

 

 

600

 

 

 

2,033

 

 

 

3,519

 

Net income

 

$

1,500

 

 

$

2,634

 

 

$

6,232

 

 

$

13,168

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.05

 

 

$

0.08

 

 

$

0.20

 

 

$

0.41

 

Diluted

 

$

0.05

 

 

$

0.08

 

 

$

0.20

 

 

$

0.41

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares of common stock outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

31,558

 

 

 

31,955

 

 

 

31,538

 

 

 

32,095

 

Diluted

 

 

31,684

 

 

 

31,981

 

 

 

31,609

 

 

 

32,121

 

 

HEALTHSTREAM, INC.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

55,459

 

 

$

36,566

 

Marketable securities

 

 

5,095

 

 

 

9,928

 

Accounts and unbilled receivables, net

 

 

30,745

 

 

 

46,100

 

Prepaid and other current assets

 

 

20,957

 

 

 

22,131

 

Total current assets

 

 

112,256

 

 

 

114,725

 

 

 

 

 

 

 

 

 

 

Capitalized software development, net

 

 

31,250

 

 

 

26,631

 

Property and equipment, net

 

 

18,333

 

 

 

22,218

 

Operating lease right of use assets, net

 

 

25,869

 

 

 

28,081

 

Goodwill and intangible assets, net

 

 

271,459

 

 

 

279,155

 

Deferred tax assets

 

 

974

 

 

 

974

 

Deferred commissions

 

 

22,860

 

 

 

19,907

 

Other assets

 

 

11,713

 

 

 

8,622

 

Total assets

 

$

494,714

 

 

$

500,313

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable, accrued and other liabilities

 

$

27,373

 

 

$

38,266

 

Deferred revenue

 

 

74,577

 

 

 

81,176

 

Total current liabilities

 

 

101,950

 

 

 

119,442

 

Deferred tax liabilities

 

 

18,205

 

 

 

14,523

 

Deferred revenue, non-current

 

 

1,915

 

 

 

1,603

 

Operating lease liability, noncurrent

 

 

26,852

 

 

 

28,479

 

Other long-term liabilities

 

 

3,594

 

 

 

2,204

 

Total liabilities

 

 

152,516

 

 

 

166,251

 

 

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

273,573

 

 

 

271,784

 

Accumulated other comprehensive income

 

 

115

 

 

 

1

 

Retained earnings

 

 

68,510

 

 

 

62,277

 

Total shareholders' equity

 

 

342,198

 

 

 

334,062

 

Total liabilities and shareholders' equity

 

$

494,714

 

 

$

500,313

 

 

 

HEALTHSTREAM, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2021

 

 

2020

 

Operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

6,232

 

 

$

13,168

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

27,443

 

 

 

22,005

 

Stock based compensation

 

 

2,260

 

 

 

1,665

 

Amortization of deferred commissions

 

 

6,900

 

 

 

6,555

 

Deferred income taxes

 

 

2,066

 

 

 

2,330

 

Provision for doubtful accounts

 

 

99

 

 

 

160

 

Loss on equity method investments

 

 

258

 

 

 

8

 

Non-cash paid time off expense

 

 

(1,011

)

 

 

?

 

Non-cash royalty expense

 

 

?

 

 

 

(3,440

)

Change in fair value of non-marketable equity investments

 

 

?

 

 

 

(1,181

)

Other

 

 

132

 

 

 

321

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts and unbilled receivables

 

 

13,907

 

 

 

(9

)

Prepaid and other assets

 

 

(8,959

)

 

 

(4,019

)

Accounts payable, accrued and other liabilities

 

 

(6,668

)

 

 

(3,668

)

Deferred revenue

 

 

(6,223

)

 

 

(3,142

)

Net cash provided by operating activities

 

 

36,436

 

 

 

30,753

 

 

 

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

 

 

 

Business combinations, net of cash acquired

 

 

(731

)

 

 

(21,449

)

Changes in marketable securities

 

 

4,708

 

 

 

(1,656

)

Payments to acquire non-marketable equity investments

 

 

?

 

 

 

(1,257

)

Payments to acquire equity method investments

 

 

(1,750

)

 

 

?

 

Purchases of property and equipment

 

 

(2,602

)

 

 

(1,734

)

Payments associated with capitalized software development

 

 

(16,577

)

 

 

(12,366

)

Net cash used in investing activities

 

 

(16,952

)

 

 

(38,462

)

 

 

 

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

 

 

 

Taxes paid related to net settlement of equity awards

 

 

(471

)

 

 

(429

)

Repurchases of common stock

 

 

?

 

 

 

(16,352

)

Payment of cash dividends

 

 

(19

)

 

 

(40

)

Net cash used in financing activities

 

 

(490

)

 

 

(16,821

)

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(101

)

 

 

(1

)

Net increase (decrease) in cash and cash equivalents

 

 

18,893

 

 

 

(24,531

)

Cash and cash equivalents at beginning of period

 

 

36,566

 

 

 

131,538

 

Cash and cash equivalents at end of period

 

$

55,459

 

 

$

107,007

 

 

Reconciliation of GAAP to Non-GAAP Financial Measures(1)

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

GAAP net income

 

$

1,500

 

 

$

2,634

 

 

$

6,232

 

 

$

13,168

 

Deferred revenue write-down

 

 

805

 

 

 

75

 

 

 

3,657

 

 

 

355

 

Interest income

 

 

(24

)

 

 

(88

)

 

 

(64

)

 

 

(919

)

Interest expense

 

 

33

 

 

 

26

 

 

 

99

 

 

 

76

 

Income tax provision

 

 

186

 

 

 

600

 

 

 

2,033

 

 

 

3,519

 

Stock based compensation expense

 

 

861

 

 

 

557

 

 

 

2,260

 

 

 

1,665

 

Depreciation and amortization

 

 

9,141

 

 

 

7,406

 

 

 

27,443

 

 

 

22,005

 

Non-cash paid time off expense

 

 

?

 

 

 

?

 

 

 

(1,011

)

 

 

?

 

Change in fair value of non-marketable equity investments

 

 

?

 

 

 

?

 

 

 

?

 

 

 

(1,181

)

Non-cash royalty expense

 

 

?

 

 

 

?

 

 

 

?

 

 

 

(3,440

)

Adjusted EBITDA

 

$

12,502

 

 

$

11,210

 

 

$

40,649

 

 

$

35,248

 

 

(1) Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release.

Reconciliation of GAAP to Non-GAAP Financial Measures

Financial Outlook for 2021

(In thousands)

(Unaudited)

 

 

 

Low

 

 

High

 

Net income

 

$

6,300

 

 

$

7,500

 

Deferred revenue write-down

 

 

4,000

 

 

 

4,000

 

Interest income

 

 

(100

)

 

 

(100

)

Interest expense

 

 

100

 

 

 

100

 

Income tax provision

 

 

2,100

 

 

 

2,600

 

Stock based compensation expense

 

 

3,000

 

 

 

3,000

 

Depreciation and amortization

 

 

36,600

 

 

 

36,900

 

Non-cash paid time off expense

 

 

(1,000

)

 

 

(1,000

)

Adjusted EBITDA

 

$

51,000

 

 

$

53,000

 

This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2021 as well as the anticipated impact of the COVID-19 pandemic on our financial results, that involve risks and uncertainties regarding HealthStream. These statements are based upon management's beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including, without limitation, as the result of developments related to the COVID-19 pandemic, including, without limitation, related to the length and severity of the pandemic; the timing, availability, effectiveness and acceptance of medical treatments and vaccines with respect to COVID-19 and associated levels of vaccination; the spread of potentially more contagious and/or virulent forms of the virus, including possible strains that may be resistant to currently available vaccines; the impact of the pandemic on general economic conditions, including with respect to competitive labor market conditions and supply chain shortages and disruptions, the impact on the pandemic on healthcare organizations; measures we are taking to respond to the pandemic; and the impact of governmental action and regulation in connection with the pandemic (including the CARES Act and other federal stimulus measures, as well as vaccine mandates); as well as risks referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed on February 25, 2021, and in the Company's other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management's views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.


These press releases may also interest you

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. . Shareholders who purchased shares of AMPL during...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...



News published on and distributed by: